205 related articles for article (PubMed ID: 23307031)
1. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies.
Matlawska-Wasowska K; Ward E; Stevens S; Wang Y; Herbst R; Winter SS; Wilson BS
Leukemia; 2013 Jun; 27(6):1263-74. PubMed ID: 23307031
[TBL] [Abstract][Full Text] [Related]
2. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
[TBL] [Abstract][Full Text] [Related]
3. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
[TBL] [Abstract][Full Text] [Related]
4. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
Herbst R; Wang Y; Gallagher S; Mittereder N; Kuta E; Damschroder M; Woods R; Rowe DC; Cheng L; Cook K; Evans K; Sims GP; Pfarr DS; Bowen MA; Dall'Acqua W; Shlomchik M; Tedder TF; Kiener P; Jallal B; Wu H; Coyle AJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):213-22. PubMed ID: 20605905
[TBL] [Abstract][Full Text] [Related]
6. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.
Iida S; Kuni-Kamochi R; Mori K; Misaka H; Inoue M; Okazaki A; Shitara K; Satoh M
BMC Cancer; 2009 Feb; 9():58. PubMed ID: 19226457
[TBL] [Abstract][Full Text] [Related]
7. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
8. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.
Lang P; Barbin K; Feuchtinger T; Greil J; Peipp M; Zunino SJ; Pfeiffer M; Handgretinger R; Niethammer D; Fey GH
Blood; 2004 May; 103(10):3982-5. PubMed ID: 14764538
[TBL] [Abstract][Full Text] [Related]
9. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
10. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
Breton CS; Nahimana A; Aubry D; Macoin J; Moretti P; Bertschinger M; Hou S; Duchosal MA; Back J
J Hematol Oncol; 2014 Apr; 7():33. PubMed ID: 24731302
[TBL] [Abstract][Full Text] [Related]
12. Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC.
Liu SD; Chalouni C; Young JC; Junttila TT; Sliwkowski MX; Lowe JB
Cancer Immunol Res; 2015 Feb; 3(2):173-83. PubMed ID: 25387893
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
14. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.
Kellner C; Zhukovsky EA; Pötzke A; Brüggemann M; Schrauder A; Schrappe M; Kneba M; Repp R; Humpe A; Gramatzki M; Peipp M
Leukemia; 2013 Jul; 27(7):1595-8. PubMed ID: 23277329
[No Abstract] [Full Text] [Related]
15. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
16. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.
Gallagher S; Turman S; Yusuf I; Akhgar A; Wu Y; Roskos LK; Herbst R; Wang Y
Int Immunopharmacol; 2016 Jul; 36():205-212. PubMed ID: 27163209
[TBL] [Abstract][Full Text] [Related]
19. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]